KR20090022595A - Ppars activator from green tea for anti-aging and moisturizing effect - Google Patents

Abstract

A PPARs(peroxisome proliferator activated receptors) active material derived from green tea leaves is provided to suppress MMP-1 through activation of PPARs-beta and PPAR-gamma and improve skin moisturization. A PPARs(peroxisome proliferator activated receptors) active material derived from green tea leaves comprises astragalin-2'-galactosyl-6'-rhamnoside represented by the formula 1 and astragalin-2'-xylosyl-6'-rhamnoside represented by the formula 2. The contents of the astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xylosyl-6'-rhamnoside are 0.0001-10wt% on a total weight basis of a moisturizing-purposed composition.

Description

PPARs activator from green tea for anti-aging and moisturizing effect

The present invention relates to a PPARs active substance that exhibits anti-aging and moisturizing action, and more particularly, to inhibit aging by inhibiting MMP-1 through promoting β and γ activity of Peroxysome Proliferator activated Receptors (PPARs). Astragalin-2'-galactosyl-6'-rhamnoside and / or astragalin isolated from green tea ( Camellia sinensis ) extract to improve and increase skin moisturizing Astragalin-2'-xylosyl-6'-rhamnoside.

Peroxysome proliferator activated receptors (PPARs) are a type of nuclear hormone receptors (nuclear hormone receptors), so far three isotypes (α, β, γ) have been reported. Although there is a difference in function depending on the tissues in which each exists, it is generally activated by binding to a specific ligand and by promoting the transcription by binding to a promoter of the protein, thereby increasing the expression of the target protein. Induces physiological changes.

Early studies on PPARs mainly focused on lipid metabolism, but currently, various functions related to aging, inflammation, and moisturizing have been reported.

First, PPARs play an important role in the proliferation and differentiation of skin, adipocytes and osteoblasts. PPAR-α promotes gene replication and cell division in rodent cells, and PPAR-γ is known to be involved in the differentiation of adipocytes and osteoblasts. In particular, embryonic stem cells without PPAR-γ did not differentiate into adipocytes (Mol Cell 1999; 4: 611-7), and spontaneously differentiated into osteoblasts (J Clin Invest 2004; 113: 846-55). . In addition, PPAR-α, -β, and -γ are all known to promote differentiation of keratinocytes, and to promote the differentiation of sebocytes and the formation of sebum (Mol Genet Metab 2001; 74: 362-9).

PPARs also affect the body's anti-inflammatory and skin tissue regeneration by interacting with immune and tissue regeneration systems in cells. When PPARs are activated, they inhibit anti-inflammatory activity by inhibiting IL-6 production and NF-κB and AP-1 functions. In particular, PPAR-γ has been reported to inhibit the immune response by inhibiting the production of inflammatory cytokines such as TNF-α, IL-6, IL-1β, gelatinase B, NO ( Nature 1998; 391: 82-6 et al.

When PPAR-α and β are activated, they promote skin tissue regeneration and are effective in wound healing. TNF-α secreted by activation of PPAR-α activates PPAR-β through the SAPK / AP-1 signaling system, which activates cell growth through interaction with PDK1, AKT1 / PKB, and Smad3. Regenerates skin by performing a function of quiescence or cell survival (Genes Dev. 2001; 15: 3263-77, EMBO J. 2004; 23: 4211-21, J. Biol. Chem., 2005; 280: 18163-70 ).

Activation of PPARs also leads to inhibition of proinflammatory factors such as NF-kB and AP-1 and ultimately inhibits the production of cytokines and MMPs (Mol Med. 2006: 12 (1-3): 17- 24 et al.). As a result, the breakdown of collagen, a major component of the dermis, can be reduced, thereby improving wrinkle formation of the skin. In relation to antioxidants, PPARs remove the active oxygen species in the body by regulating the expression of uncoupling protein-2, catalase, and copper / zinc SOD, enzymes that remove free radical species. Aging may be improved (J. Immunol. 2006 Sep 15; 177 (6): 3737-45).

Many kinds of PPARs active materials have been discovered to date, but most of them are reported in the form of extracts whose exact efficacy and composition are unknown.

Therefore, the inventors of the present invention, while researching to find an excellent PPAR active material derived from nature, prepared an extract from green tea using water or an organic solvent, and then separated the active ingredient from the extract through a purification process and silica gel column chromatography. As a result of confirming the PPAR activation effect of the substances and measuring the inhibition of collagenase (MMP-1) degradation and skin moisturizing effect, astragalin-2'-galactosyl-6'-rhamnoside and astragalin derived from green tea extract It was confirmed that -2'-xylyl-6'-rhamnoside has the effect of inhibiting MMP-1 and skin moisturizing effect through PPAR activity and completed the present invention.

Accordingly, it is an object of the present invention to provide a substance that exhibits anti-aging and moisturizing effects through PPARs activation effect.

In the present invention, Perisome Proliferator activated Receptors (PPARs) by inhibiting MMP-1 through the promotion of β and γ activity to improve aging and skin moisturizing, isolated from green tea ( Camellia sinensis ) extract Astragalin-2'-galactosyl-6'-rhamnoside represented by Formula 1 and / or Astragalin-2'-xyloxy represented by Formula 2 Astragalin-2'-xylosyl-6'-rhamnoside is provided:

In another aspect, the present invention provides an anti-aging or moisturizing composition containing the astragalin-2'-galactosyl-6'-rhamnoside and / or astragalin-2'-xyloxy-6'-rhamnoside. .

PPAR-β when Astragalin-2'-galactosyl-6'-rhamnoside and Astragalin-2'-xyloxy-6'-rhamnoside isolated from green tea extract according to the present invention were applied to the skin And PPAR-γ inhibited MMP-1 and finally delayed or improved skin aging, increased recovery of damaged skin barrier and increased skin moisturization.

Hereinafter, the present invention will be described in more detail.

In the present invention, a green tea extract containing astragalin glycosides is prepared from green tea using water or an organic solvent, and the process is as follows:

(1) Put about 1 to 6 times, preferably about 3 times, hexane of green tea into green tea seeds or leaves (not limited to this), extract and degrease while stirring 1 to 5 times at room temperature.

② About 1 to 8 times, preferably about 4 times of water, methanol or ethanol to the degreased plants, extracted by refluxing 1 to 5 times, immersed at 10 to 20 ℃ for 1 to 3 days, then filtered and centrifuged Separation separates the residue and the filtrate.

③ The extracted filtrate is concentrated under reduced pressure, and the extract is suspended in water, followed by ether removal.

④ Extract the aqueous layer 1-5 times with ethyl acetate, etc., and then concentrate the resulting ethyl acetate layer under reduced pressure to obtain an extract.

⑤ The extract is dissolved in a small amount of methanol and the like, and a large amount of ethyl acetate is added to dry the resulting precipitate to obtain a green tea extract containing astragalin glycosides.

In the present invention, it is preferable to use hexane as the organic solvent used to prepare the green tea extract containing the astragalin glycoside, but is not limited thereto.

Astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xyl from the green tea extract containing the above-mentioned astragalin glycosides The process for separating the sil-6'-rhamnoside (Astragalin-2'-xylosyl-6'-rhamnoside) is as follows.

After extracting by adding a mixed solution of an organic solvent and water to the green tea-derived extract, the active ingredient is separated through a purification process. The green tea-derived extract is added to a solution having a mass ratio of organic solvent and water of 80/20 to 50/50 and mixed. Organic solvents used for the extraction efficiency in the present invention include ethanol, methanol, acetone and tetrahydrofuran. After adding 5 to 10 times the amount of the organic solvent and water mixed solution of green tea extract and treating, the components present in the extract may be separated by stirring at 20 to 70 ° C. for 10 to 120 minutes.

After extracting the water-soluble substance from the green tea-derived extract as described above, in order to remove the residue remaining in the reaction solution, centrifugation or filter aid is added and separated by filtration with a filter. Filtration methods include pressure filtration, centrifugal filtration, suction filtration, and the like, and preferably PPARs active materials can be prepared using pressure filtration. The filtrate, from which the residue was removed, was concentrated under reduced pressure to obtain a crude product, and the crude product obtained was separated by silica gel column chromatography (chloroform: methanol = qa`7: 1 to 3: 1) to show active ingredients and other Kam which exhibit PPARs activity. Ferrol glycosides can be obtained.

In order to identify the active ingredient of the green tea extract obtained from the above experiment, molecular weight was confirmed by FAB-MS analysis, and NMR structure analysis was performed (Varian Gemini 2000 300MHz, Varian).

The present invention relates to an anti-aging composition containing the above-mentioned astragalin-2'-galactosyl-6'-rhamnoside and / or astragalin-2'-xyloxy-6'-rhamnoside.

The present invention also relates to a moisturizing composition containing the above-mentioned astragalin-2'-galactosyl-6'-rhamnoside and / or astragalin-2'-xyloxy-6'-rhamnoside.

The anti-aging or moisturizing composition according to the present invention may contain the active ingredients in an amount of 0.0001 to 10% by weight, respectively, based on the total weight of the composition.

Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples, but the present invention is not limited only to these examples.

Example 1 Preparation of Green Tea Seed Extract

6 kg of hexane was added to 2 kg of green tea seeds, and extracted by stirring three times at room temperature. Then, 4 L of 80% methanol was added to 1 kg of degreased green tea seeds, and refluxed three times, followed by immersion at 15 ° C. for 1 day. Thereafter, the residue and the filtrate were separated through filter cloth filtration and centrifugation. The separated filtrate was concentrated under reduced pressure, suspended in water, extracted five times with 1 L of ether to remove the pigment, and the aqueous layer was 1-butanol. Extracted three times with 500 ml. The total 1-butanol layer thus obtained was concentrated under reduced pressure to obtain a 1-butanol extract, which was dissolved in a small amount of methanol, and then added to a large amount of ethyl acetate to dry the resulting precipitate, thereby obtaining 250 g of green tea seed extract.

Example 2 Separation of Active Ingredients by Silica Gel Column Chromatography

20 times (v / w) of 70% ethanol solution (v / v) was added to 10 g of the green tea extract obtained in Example 1, followed by stirring in a 60 ° C. reactor for 2 hours to extract the active ingredient. In order to remove the residue remaining in the reaction solution, the precipitate and the supernatant were separated using a centrifugal separator, and the supernatant was collected and concentrated under reduced pressure to obtain a crude product. The obtained crude product was separated using silica gel column chromatography (chloroform: methanol = 4: 1), and two active ingredients containing an astragalin glycoside material were obtained as 1.95 g and 1.65 g, respectively.

Example 3 Identification of PPAR Active Substances

The two active ingredients of the green tea extract obtained from Example 2 exhibited the following characteristics, respectively, such as astragalin-2'-galactosyl-6'-rhamnoside and astragallin-2'-xylyl-6 ' -Identified as rhamnoside (Varian Gemini 2000 300MHz, Varian).

<Physicochemical Properties of Astragalin-2'-Galactosyl-6'-Rhamnoside>

[Formula 1]

Appearance: Yellow fine crystal

Positive FAB-MS: 757 [M + H] +

¹ H NMR: 8.02 (2H, d, H2 ', 6'), 6.90 (2H, d, H3 ', 5'), 6.38 (1H, s, H8), 6.19 (1H, s, H6), 5.33 ( 1H, d, H1, 4.76 (1H, d, H1), 4.47 (1H, d, H1), 3.8-3.2 (16H, m), 1.10 (3H, d, H6).

¹³ C-NMR: 158.7, 134.5, 179.2, 161.6, 101.0, 162.8, 95.7, 159.3, 105.0, 123.0, 132,4, 116.3, 159.3, 101.2, 82.3, 78.3, 72.1, 77.8, 68.3, 102.3, 72.3, 73.9 , 71.4, 69.7, 17.9, 104.6, 75.4, 76.9, 71.2, 77.8, 62.4.

<Physicochemical Properties of Astragalin-2'-Xyloxy-6'-Rhamnoside>

[Formula 2]

Appearance: Yellow fine crystal

Positive FAB-MS: 727 [M + H] +

¹ H NMR: 8.05 (2H, d, H2 ', 6'), 6.89 (2H, d, H3 ', 5'), 6.34 (1H, s, H8), 6.16 (1H, s, H6), 5.37 ( 1H, d, H1, 4.78 (1H, d, H1), 4.49 (1H, s, H1), 4.0-3.2 (15H, m), 1.10 (3H, d, H6).

¹³ C-NMR: 158.7, 134.5, 179.2, 161.6, 101.0, 162.8, 95.7, 159.3, 105.0, 123.0, 132,4, 116.3, 159.3, 101.2, 82.3, 78.3, 72.1, 77.8, 68.3, 102.3, 72.3, 73.9 , 71.4, 69.7, 17.9, 104.6, 75.4, 76.9, 71.2, 77.8, 62.4.

Test Example 1 Evaluation of PPARs Activation Efficacy

PPARs activation efficacy evaluation was performed on the astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xyloxy-6'-rhamnoside isolated in Example 3. As a positive control group, camphorol, camphorol-3-O-lutinoside, and camphorol-3-O-glucoside were used at concentrations of 1 μM, respectively.

Normal monkey kidney epithelial cell line CV-1 cells (ATCC CCL 70) were passaged in DMEM medium containing charcoal / dextran treated 10% fetal bovine serum, eliminating the estrogen effect of phenol red. Phenol free medium was used for this purpose. The plasmid (Source: Dr. Ron Evans, Solk institute) is a PPRE (PPARs response element) that is activated by the binding of PPARs (genetic and ligand-binding PPARs) followed by universal promoters that are expressed under normal culture conditions. It has a firefly luciferase gene which is taken as a promoter and later serves as a reporter, and one in which the universal promoter to be used is bound to the renilla luciferase gene.

Dispense CV-1 cells in a 24-hole well plate at a concentration of 5x10 ⁴ and incubate for 24 hours at 5% CO ₂ and 37 ° C. Mixture of the plasmids with DMEM and PEI (Polyethylenimine) at room temperature After reacting for 15 minutes, plasmids were transfected into the cells by spraying the respective wells.

After 24 hours of treatment, the cells were washed twice with cold PBS, and the cells were destroyed by treating the cells with reporter lysis buffer (Promega) for 10 minutes. The cell eluate thus obtained was transferred to a micro tube and centrifuged at 12,000 rpm for 3 minutes to separate cell residues, thereby obtaining pure cell eluate.

PPAR activity of each test substance was mixed with Luciferase substrate (Promega) in the cell eluate at a 4: 1 ratio, and the amount of light emitted by the luminometer was measured. In addition, the cell eluate was treated with the same amount of 2X β-galactosidase enzyme assay buffer (Promega), reacted at 37 ° C. for 30 minutes, and then measured for absorbance at 420 nm. The galactosidase activity was compared and the results are shown in FIGS.

1 and 2, astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xyloxy-6'-rhamnoside according to the present invention are camphorols as positive controls. , Camphorol-3-O-rutinoside, camphorol-3-O-glucoside was found to have superior PPAR-β and -γ activity.

Test Example 2 Collagenase (MMP-1) Inhibitory Activity

Human fibroblasts were placed in a 96-well microtiter plate containing Dulbecco's Modified Eagle's Media (DMEM) medium containing 2.5% fetal bovine serum at 5,000 cells / well, 70-70 5% CO ₂ , 37 ° C. were incubated in an incubator until it grew about 80%. Astragalin-2'-galactosyl-6'-rhamnoside and Astragalin-2'-xyloxy-6'-rhamnoside isolated in Example 3; And the positive control retinoic acid, camphorol, camphorol-3-O-lutinoside, and camphorol-3-O-glucoside, respectively, at 10 ^-4 molar concentration for 24 hours, and then the cell culture solution was collected. . The degree of collagenase production was measured by using a commercially available collagenase measuring instrument (Amersham Pharmacia, USA Catalog #: RPN 2610). First, the cell cultures collected in a 96-well plate uniformly coated with primary collagenase antibody were put in an antigen-antibody reaction for 3 hours. After 3 hours, the chromophore-conjugated secondary collagen antibody was placed in a 96-well plate incubator and reacted for 15 minutes. After 15 minutes, 3,3 ', 5,5'-tetramethylbenzidine (3,3', 5,5'-tetramethylbenzidine; sigma), a color-causing substance, was added and developed at room temperature for 15 minutes, followed by 1M sulfuric acid. When the reaction is stopped, the color of the reaction solution becomes yellow, and the degree of yellow color varies depending on the progress of the reaction. The absorbance of the yellowish 96-well plate incubator (96-well plate) was measured at 405 nm using an absorbance meter, and the degree of synthesis of collagenase was calculated by Equation 1 below. At this time, the reaction absorbance of the cell culture of the group not treated with the composition was used as a control.

Collagenase expression level (%) = (absorbance of material treated cell group / absorbance of control group) × 100

compound Expression degree (%) Untreated group 100 Retinoic acid 75 Astragalin-2'-galactosyl-6'-rhamnoside 77 Astragalin-2'-Xyloxy-6'-Rhamnoside 79 Camphorol 91 Camperol-3-O-Lutinoside 92 Camperol-3-O-Glucoside 93

In the results of Table 1, astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xyloxy-6'-rhamnoside according to the present invention are equivalent to those of the positive control group. It was confirmed that the substrate metal has an effect of inhibiting protease (MMP-1) or more.

Test Example 3 Measurement of Skin Barrier Function Recovery and Skin Moisturizing Effect in Hairless Mouse Skin

The effects of astragalin-2'-galactosyl-6'-rhamnoside and astragallin-2'-xyloxy-6'-rhamnoside isolated in Example 3 on the skin barrier recovery and increase in moisturizing power were measured. It was.

Acetone was applied twice a day for 5 days on the back of hairless mice (Charles River, Japan) 8 to 10 weeks after birth to induce loss of barrier function of skin such as experimental animals, and then TEWL ( Vehicles and astragalins containing propylene glycol and ethanol in a 7: 3 ratio were used only for experimental animals with skin that measured transepidermal water loss (Dermal moisture loss) and showed transdermal water loss of 40 g / ㎡ / hr or more. -2'-galactosyl-6'-rhamnoside and astragalin-2'-xyloxy-6'-rhamnoside; And a positive control group of retinoic acid, camphorol, camphorol-3-O-lutinoside and camphorol-3-O-glucoside, each at a concentration of 1%, twice a day at a dose of 200ul per 5 cm2 of skin area. Continuous application for 3 days. TEWL was measured at regular intervals after treatment, and the results are shown in FIG. 3. In addition, the skin moisture content was simultaneously measured using a coronometer (Corneometer, German Courage Khazaka), the results are shown in FIG. At this time, the skin moisture content of the untreated group was also measured.

In the results of Figure 3, the astragalin-2'-galactosyl-6'-rhamnoside and the astragalin-2'-xyloxy-6'-rhamnoside treated group according to the present invention are used in vehicle and other camphorol glycosides. Barrier damage was recovered more quickly than the treatment group.

In addition, in the results of Figure 4, astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xyloxy-6'-rhamnoside treated group according to the present invention were used in vehicle and other camphorols. It was confirmed that the skin moisture content is higher than that of the glycoside treatment group.

To summarize the results so far, astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xyloxy-6'-rhamnoside prepared in Example 3 of the present invention Each of them has very good activity against PPAR-β and PPAR-γ, and it is confirmed that the effect is excellent in improving aging by inhibiting MMP-1, repairing damaged skin barrier and increasing skin moisturizing power.

1 is astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xyloxy-6'-rhamnoside isolated from green tea extract according to the present invention, and other camphorol glycosides It is a graph showing the effect on the activity of peroxysome proliferation active receptor beta.

Figure 2 shows astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xyloxy-6'-rhamnoside isolated from the green tea extract according to the present invention, and other camphorol glycosides It is a graph showing the effect on the activity of the peroxysomal proliferation active receptor gamma.

3 is astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xyloxy-6'-rhamnoside isolated from green tea extracts according to the present invention, and other camphorol glycosides A graph showing the effect on the repair of damaged skin barriers.

Figure 4 shows astragalin-2'-galactosyl-6'-rhamnoside and astragalin-2'-xyloxy-6'-rhamnoside isolated from green tea extract according to the present invention, and other camphorol glycosides This graph shows the effect on skin moisture.

Claims (6)

Astragalin-2'-galactosyl-6'-rhamnoside represented by Formula 1 below: [Formula 1]

Astragalin-2'-xyloxy-6'-rhamnoside represented by Formula 2 below: [Formula 2]

Astragalin-2'-galactosyl-6'-rhamnoside and Astragalin-2'-xyloxy-6'-rhamnoside xyloroside-6'-rhamnoside) anti-aging composition containing one or more selected from the group consisting of as an active ingredient. Astragalin-2'-galactosyl-6'-rhamnoside and Astragalin-2'-xyloxy-6'-rhamnoside xyloroside-6'-rhamnoside) Moisturizing composition containing at least one selected from the group consisting of as an active ingredient. Astragalin-2'-galactosyl-6'-rhamnoside and Astragalin-2'-xyloxy-6'-rhamnoside xyloroside-6'-rhamnoside) composition for promoting PPARs activity containing at least one selected from the group consisting of active ingredients. 6. The composition of any one of claims 3 to 5, wherein the astragallin-2'-galactosyl-6'-rhamnoside and the astragallin-2'-xyloxy-6'-rhamnoside are the total weight of the composition. Composition in an amount of 0.0001 to 10% by weight, respectively.

Images